There are thus several mTORC1, dual mTOR inhibitors and mixed mTOR/PI3K inhibitors in development or in clinical trials already that may be useful to minimize clinical pulmonary fibrosis [71,84,123]. The gene discussed is MTOR; the disease is pulmonary fibrosis.